MedTrace Logo

Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration

NCT04270669 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2022-01-10

No results posted yet for this study

Summary

This is a non-randomized, open-label, multicenter, 48-week study to investigate the efficacy, safety and pharmacokinetics of RC28-E injection in the treatment of patients with wet age-related macular degeneration by multiple administration.

Conditions

Interventions

BIOLOGICAL

intravitreal injection of RC28-E 0.5mg

The patient received one treatment of RC28-E 0.5mg in the test group

BIOLOGICAL

intravitreal injection of RC28-E 1.0mg

The patient received one treatment of RC28-E 1.0mg in the test group

BIOLOGICAL

intravitreal injection of RC28-E2.0mg

The patient received one treatment of RC28-E 2.0mg in the test group

Sponsors & Collaborators

  • RemeGen Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-15
Primary Completion
2021-10-29
Completion
2021-10-29

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04270669 on ClinicalTrials.gov